hotspot -WSS

hotspot

author：hotspot 2025-09-05 03:01:30 - browse：3851

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Scientists successfully use ultrasound imaging to map brain activity

WSS

ASCO eve: Let’s set the table for this year's meeting

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Investigation reveals sickle cell patients pressured into sterilizations

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Eyeing GLP

Fentanyl is making it harder to start addiction treatment

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Scientists successfully use ultrasound imaging to map brain activity

Peter Hotez and the public health issue of online harassment

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: More tumult at BIO & coercive care for sickle cell patients

As demand for Covid shots wanes, Moderna seeks its next success

Lab trade group sues FDA to halt regulation of lab

hotspot

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Lab trade group sues FDA to halt regulation of lab

FDA poised to publish guidelines for clinical trial diversity

iTeos Therapeutics debuts first data on TIGIT

Startling documents reveal new facets of Sacklers' opioid empire

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

knowledge

Wikipedia

focus

entertainment